Joshua Phillips Sells 12,710 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,710 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.40, for a total transaction of $94,054.00. Following the completion of the sale, the director now directly owns 5 shares of the company’s stock, valued at $37. This trade represents a 99.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Joshua Phillips also recently made the following trade(s):

• On Monday, January 13th, Joshua Phillips sold 12,163 shares of Sera Prognostics stock. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57.

Sera Prognostics Trading Up 0.6 %

SERA opened at $6.37 on Wednesday. The company has a market cap of $215.13 million, a P/E ratio of -6.43 and a beta of 0.86. Sera Prognostics, Inc. has a 12 month low of $4.98 and a 12 month high of $12.35. The business’s 50-day moving average price is $7.44 and its 200-day moving average price is $7.31.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.09 million. During the same period in the prior year, the firm earned ($0.23) EPS. Equities research analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Several institutional investors and hedge funds have recently bought and sold shares of SERA. JPMorgan Chase & Co. lifted its stake in Sera Prognostics by 7,357.8% in the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock worth $6,902,000 after acquiring an additional 873,002 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock worth $892,000 after purchasing an additional 75,441 shares during the period. Sanders Morris Harris LLC boosted its stake in shares of Sera Prognostics by 165.7% during the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock valued at $725,000 after purchasing an additional 56,500 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Sera Prognostics by 8.9% during the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock valued at $4,578,000 after buying an additional 47,969 shares during the period. Finally, State Street Corp raised its stake in Sera Prognostics by 8.8% in the third quarter. State Street Corp now owns 425,093 shares of the company’s stock worth $3,316,000 after buying an additional 34,479 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.